282 related articles for article (PubMed ID: 29269360)
1. Management of atypical femoral fracture in a patient with osteogenesis imperfecta.
Tan JY; Seow CJ
BMJ Case Rep; 2017 Dec; 2017():. PubMed ID: 29269360
[TBL] [Abstract][Full Text] [Related]
2. Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur.
Greenspan SL; Vujevich K; Britton C; Herradura A; Gruen G; Tarkin I; Siska P; Hamlin B; Perera S
Osteoporos Int; 2018 Feb; 29(2):501-506. PubMed ID: 29085957
[TBL] [Abstract][Full Text] [Related]
3. Do femoral fractures in adult patients with osteogenesis imperfecta imitate atypical femoral fractures? A case series.
Andersen JD; Bünger MH; Rahbek O; Hald JD; Harsløf T; Langdahl BL
Osteoporos Int; 2019 Feb; 30(2):513-517. PubMed ID: 30448959
[TBL] [Abstract][Full Text] [Related]
4. Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta.
Liu W; Lee B; Nagamani SCS; Nicol L; Rauch F; Rush ET; Sutton VR; Orwoll E
J Clin Endocrinol Metab; 2023 Jun; 108(7):1787-1796. PubMed ID: 36658750
[TBL] [Abstract][Full Text] [Related]
5. Osteogenesis imperfecta: from diagnosis and multidisciplinary treatment to future perspectives.
Bregou Bourgeois A; Aubry-Rozier B; Bonafé L; Laurent-Applegate L; Pioletti DP; Zambelli PY
Swiss Med Wkly; 2016; 146():w14322. PubMed ID: 27346233
[TBL] [Abstract][Full Text] [Related]
6. Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society.
van de Laarschot DM; McKenna MJ; Abrahamsen B; Langdahl B; Cohen-Solal M; Guañabens N; Eastell R; Ralston SH; Zillikens MC
J Clin Endocrinol Metab; 2020 May; 105(5):1682-99. PubMed ID: 31867670
[TBL] [Abstract][Full Text] [Related]
7. Recurrence of bilateral atypical femoral fractures associated with the sequential use of teriparatide and denosumab: a case report.
Ramchand SK; Chiang CY; Zebaze RM; Seeman E
Osteoporos Int; 2016 Feb; 27(2):821-5. PubMed ID: 26458389
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up in osteogenesis imperfecta type VI.
Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
[TBL] [Abstract][Full Text] [Related]
9. Teriparatide treatment in an adult patient with hypophosphatasia exposed to bisphosphonate and revealed by bilateral atypical fractures.
Righetti M; Wach J; Desmarchelier R; Coury F
Joint Bone Spine; 2018 May; 85(3):365-367. PubMed ID: 29246529
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate long-term treatment related bilateral subtrochanteric femoral fracture. Can teriparatide be useful?
Tarazona-Santabalbina FJ; Aguilella-Fernández L
Aging Clin Exp Res; 2013 Oct; 25(5):605-9. PubMed ID: 24026625
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.
Lyu H; Zhao SS; Yoshida K; Tedeschi SK; Xu C; Nigwekar SU; Leder BZ; Solomon DH
J Clin Endocrinol Metab; 2019 Nov; 104(11):5611-5620. PubMed ID: 31265071
[TBL] [Abstract][Full Text] [Related]
12. Individualized treatment with denosumab in children with osteogenesis imperfecta - follow up of a trial cohort.
Hoyer-Kuhn H; Rehberg M; Netzer C; Schoenau E; Semler O
Orphanet J Rare Dis; 2019 Sep; 14(1):219. PubMed ID: 31533771
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
[TBL] [Abstract][Full Text] [Related]
14. Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.
Pavón de Paz I; Rosado Sierra JA; Pérez Blanco C; Modroño Móstoles N; Guijarro de Armas G; Navea Aguilera C
Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb; 66(2):108-116. PubMed ID: 30077631
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate Treatment and the Characteristics of Femoral Fractures in Children With Osteogenesis Imperfecta.
Vuorimies I; Mäyränpää MK; Valta H; Kröger H; Toiviainen-Salo S; Mäkitie O
J Clin Endocrinol Metab; 2017 Apr; 102(4):1333-1339. PubMed ID: 28323993
[TBL] [Abstract][Full Text] [Related]
17. Antiresorptive-associated spontaneous fractures of both tibiae, followed by an atypical femur fracture during the sequential treatment with alendronate, denosumab then teriparatide.
Tan J; Sano H; Poole K
BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31340943
[TBL] [Abstract][Full Text] [Related]
18. Teriparatide treatment in adult patients with osteogenesis imperfecta type I.
Gatti D; Rossini M; Viapiana O; Povino MR; Liuzza S; Fracassi E; Idolazzi L; Adami S
Calcif Tissue Int; 2013 Nov; 93(5):448-52. PubMed ID: 23907723
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Denosumab for Osteoporosis in Three Female Patients with Osteogenesis Imperfecta.
Uehara M; Nakamura Y; Takahashi J; Kamimura M; Ikegami S; Suzuki T; Uchiyama S; Yamaguchi T; Kosho T; Kato H
Tohoku J Exp Med; 2017 Jun; 242(2):115-120. PubMed ID: 28626166
[TBL] [Abstract][Full Text] [Related]
20. Sequential treatment with teriparatide and strontium ranelate in a postmenopausal woman with atypical femoral fractures after long-term bisphosphonate administration.
Lampropoulou-Adamidou K; Tournis S; Balanika A; Antoniou I; Stathopoulos IP; Baltas C; Triantafillopoulos IK; Papaioannou NA
Hormones (Athens); 2013; 12(4):591-7. PubMed ID: 24457408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
